If you have been reading about Mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
=== Mass spectrometry === Mass spectrometry is a way to quantify RNA modifications. More often than not, modifications cause an increase in mass for a given nucleoside. This gives a characteristic readout for the nucleoside and the modified counterpart. Moreover, mass spectrometry allows the investigation of modification dynamics by labelling RNA molecules with stable (non-radioactive) heavy isotopes in vivo. Due to the defined mass increase of heavy isotope labeled nucleosides they can be distinguished from their respective unlabelled isotopomeres by mass spectrometry. This method, called NAIL-MS (nucleic acid isotope labelling coupled mass spectrometry), enables a variety of approaches to investigate RNA modification dynamics.
Local promoter Randy Hauser became aware of the band at a concert and offered to pay for demo recordings. However, one day before the band was due to record at the Music Bank studio in Washington, police shut down the studio during the biggest cannabis raid in the history of the state. The final demo, completed in 1988, was named The Treehouse Tapes and found its way to music managers Kelly Curtis and Susan Silver, who also managed the Seattle-based band Soundgarden. Curtis and Silver passed the demo on to Columbia Records' A&R representative Nick Terzo, who set up an appointment with label president Don Ienner. Based on The Treehouse Tapes, Terzo signed Alice in Chains to Columbia in 1989.
Water is an inorganic compound with the chemical formula H2O. It is a transparent, tasteless, odorless, and nearly colorless chemical substance. It is the main constituent of Earth's streams, lakes, and oceans. Water is also the fluid of all known living organisms, in which it acts as a solvent. Water, being a polar molecule, undergoes strong intermolecular hydrogen bonding which is a large contributor to its physical and chemical properties. It is vital for all known forms of life, despite not providing food energy or being an organic micronutrient. Due to its presence in all organisms, its chemical stability, its worldwide abundance, and its strong polarity relative to its small molecular size, water is often referred to as the "universal solvent". Because Earth's surface temperature and pressure is relatively close to water's triple point, water exists on Earth as a solid, a liquid, and a gas. It forms precipitation in the form of rain and aerosols in the form of fog. Clouds consist of suspended droplets of water and ice, its solid state. When finely divided, crystalline ice may precipitate in the form of snow. The gaseous state of water is steam or water vapor. Water covers about 71% of the Earth's surface, with seas and oceans making up most of the water volume (about 96.5%). Small portions of water occur as groundwater (1.7%), in the glaciers and the ice caps of Antarctica and Greenland (1.7%), and in the air as vapor, clouds (consisting of ice and liquid water suspended in air), and precipitation (0.001%).
OD600 (Also written as O.D. 600, D600, o.d. 600, OD600) is an abbreviation indicating the optical density of a sample measured at a wavelength of 600 nm in 1 cm light path (unless otherwise stated). It is a commonly used in microbiology for estimating the concentration of bacteria or other cells in a liquid as the 600 nm wavelength does little to damage or hinder their growth. OD600 is a type of turbidity measurement. Since optical density in case of OD600 measurements results from light scattering by particles (cells) rather than absorption, size and shape as well as dead cells and debris of a cell may add to light dissipating. Distinctive cell types that are at densities of the same level (eg. cell/mL), may, therefore, show varying values OD600, when estimated on a similar instrument. For turbid samples such as cell cultures, the major contributor for the optical density measured is light scattering and not the result of molecular absorption following the Beer-Lambert Law. The measurements are therefore depending on the optical setup of the spectrophotometer (distance between the cell holder and instrument exit slit, monochromator optics, slit geometry, etc.), different instrument types will most likely tend to give different OD600 readings for the same turbid sample. Measuring the change of the OD600 as a function of time (e.g. measuring of the growth curve) may indicate the growth phase of cultured cell population, i.e. whether it is in the lag phase, log phase, or stationary phase.
Sources: en.wikipedia.org
18 And she revealed her whorings, and she revealed her nakedness, and so I turned from her just as I turned from her sister. 19 Yet she increased her whorings, recalling the days of her childhood when she was prostituted in the land of Egypt. 20 And she lusted after her male lovers whose genitalia were the genitalia of male donkeys and their seminal emission was the seminal emission of horses. Ezekiel 23:18–20 Lexham English Bible
== Conquest of Sumer == Eannatum, grandson of Ur-Nanshe and son of Akurgal, was a king of Lagash who conquered all of Sumer, including Ur, Nippur, Akshak (controlled by Zuzu), Larsa, and Uruk (controlled by Enshakushanna, who is on the King List). He entered into conflict with Umma, waging a war over the fertile plain of Gu-Edin. He personally commanded an army to subjugate the city-state, and vanquished Ush, the ruler of Umma, finally making a boundary treaty with Enakalle, successor of Ush, as described in the Stele of the Vultures and in the Cone of Entemena:
=== EC 2.4: glycosyl, hexosyl, and pentosyl transferases === EC 2.4 includes enzymes that transfer glycosyl groups, as well as those that transfer hexose and pentose. Glycosyltransferase is a subcategory of EC 2.4 transferases that is involved in biosynthesis of disaccharides and polysaccharides through transfer of monosaccharides to other molecules. An example of a prominent glycosyltransferase is lactose synthase which is a dimer possessing two protein subunits. Its primary action is to produce lactose from glucose and UDP-galactose. This occurs via the following pathway: UDP-β-D-galactose + D-glucose
During the trial of alleged 9/11 conspirator Zacarias Moussaoui, the U.S. government identified five people as having been completely aware of the operation's details; bin Laden, Mohammed, Mohammed Atef, Abu Turab al-Urduni, and bin al-Shibh. The attacks were conceived by Khalid Sheikh Mohammed, who first presented it to bin Laden in 1996. Many targets were listed that al-Qaeda hijackers could crash planes into, including the Library Tower (now the U.S. Bank Tower) in Los Angeles. Bin Laden rejected the plan for being too elaborate. Al-Qaeda's first attacks against the U.S. after Bin Laden's 1998 fatwa were the 1998 African embassy bombings. In late 1998 or early 1999, bin Laden approved Mohammed to go forward with a new version of the 1996 plan. Bin Laden provided leadership and financial support, and was involved in selecting participants. Atef provided operational support, including target selections and helping arrange travel for the hijackers. He initially selected Nawaf al-Hazmi and Khalid al-Mihdhar, both experienced jihadists who had fought in the Bosnian war. The two arrived in the United States in mid-January 2000. In early 2000, they took flying lessons in San Diego, California. Both spoke little English. They performed poorly in flying lessons, and so they eventually served as secondary "muscle" hijackers. The Hamburg cell in Germany included Islamists who were key operatives in the 9/11 attacks. In late 1999, cell members bin al-Shibh, Mohamed Atta, Marwan al-Shehhi, and Ziad Jarrah arrived to meet al-Qaeda in Afghanistan.
=== Vector design === DNA vaccines elicit the best immune response when high-expression vectors are used. These are plasmids that usually consist of a strong viral promoter to drive the in vivo transcription and translation of the gene (or complementary DNA) of interest. Intron A may sometimes be included to improve mRNA stability and hence increase protein expression. Plasmids also include a strong polyadenylation/transcriptional termination signal, such as bovine growth hormone or rabbit beta-globulin polyadenylation sequences. Polycistronic vectors (with multiple genes of interest) are sometimes constructed to express more than one immunogen, or to express an immunogen and an immunostimulatory protein. Because the plasmid – carrying relatively small genetic code up to about 200 Kbp – is the "vehicle" from which the immunogen is expressed, optimising vector design for maximal protein expression is essential. One way of enhancing protein expression is by optimising the codon usage of pathogenic mRNAs for eukaryotic cells. Pathogens often have different AT-contents than the target species, so altering the gene sequence of the immunogen to reflect the codons more commonly used in the target species may improve its expression. Another consideration is the choice of promoter. The SV40 promoter was conventionally used until research showed that vectors driven by the Rous Sarcoma Virus (RSV) promoter had much higher expression rates.
Sources: en.wikipedia.org
=== Brand names === CPA is marketed under brand names including Androcur, Androcur Depot, Androcur-100, Androstat, Asoteron, Cyprone, Cyproplex, Cyprostat, Cysaxal, Imvel, and Siterone. When CPA is formulated in combination with ethinylestradiol, it is also known as co-cyprindiol, and brand names for this formulation include Andro-Diane, Bella HEXAL 35, Chloe, Cypretil, Cypretyl, Cyproderm, Diane, Diane Mite, Diane-35, Dianette, Dixi 35, Drina, Elleacnelle, Estelle, Estelle-35, Ginette, Linface, Minerva, Vreya, and Zyrona. CPA is also marketed in combination with estradiol valerate as Climen, Climene, Elamax, and Femilar.
Ergometrine, which is a minor constituent representing up to 8% of total alkaloids, is known to produce psychedelic effects only in higher amounts (2–10 mg) than those in typical doses of morning glory seeds and hence is thought to not contribute to the effects of the seeds either. Moreover, ergometrine is present in Ipomoea tricolor and Argyreia nervosa but not in Ipomoea corymbosa. Isoergine being responsible for the hallucinogenic effects of morning glory seeds is also supported by animal studies. According to Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved) however, both ergine and isoergine are "probably correctly dismissed" as not contributing to the effects of morning glory seeds. The poorly-stable lysergic acid hydroxyethylamides (LSHs) might alternatively be involved in the psychedelic effects of morning glory seeds per Shulgin.
Chandan K. Sen is an Indian-American scientist internationally recognized for his leadership in regenerative medicine and wound care innovation. He is widely known for pioneering research and transformative technologies that are advancing the science of tissue repair and improving patient outcomes. Sen currently serves as Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. He holds the Bartley P. Griffith MD, FACS, FRCS Chair of Regenerative Medicine and is a tenured Professor of Surgery. In addition, he serves as Chief Scientific Officer for wound care services within the University of Pittsburgh Medical Center health system. At the University of Pittsburgh, Professor Sen serves as Associate Vice Chancellor for Life Sciences Innovation and Commercialization. He is the current vice-chair and chair-elect of the National Institutes of Health’s Diabetic Foot Consortium. Sen also serves as President-Elect (2027–2028) of the national Wound Healing Society. On February 13, 2024, Pennsylvania State Representatives, chaired by Rep. Chris Pielli (D-Chester), convened a hearing on the impact of generative AI. Dr. Sen led the panel on AI and Healthcare, contributing expert insights on the integration of artificial intelligence in clinical practice. Founded in 1992, the McGowan Institute for Regenerative Medicine was originally established as the McGowan Center for Artificial Organ Development. Professor Sen relocated to Pittsburgh in July 2023, bringing a large team of scientists from Indiana.
== Personal life == Prior to moving to Los Angeles, Johnny was employed as a Manager at Microsoft in Chicago, Illinois. He is an avid golfer and won The Golf Channel's 2006 The Big-Break All Star Challenge Scrubs competition, beating out Robert Maschio ("The Todd") in the final match. While attending law school at the University of Iowa, he worked as a law clerk at the U.S. Attorney's Office. He practiced law in Chicago, Illinois, at the law firms of Katten Muchin Rosenman and Dentons before becoming a Founding Member (and VP of Business Development and Strategic Partnerships) of Acorn Finance.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.